iiinova — where your digital self keeps evolving

Andrew Lloyd ALA @andrewlloydala.bsky.social · 24/09/2026

[ALA Client News] Provepharm enters fluorescence imaging market with US and UK launch of Zyogreen, its ready-to-use indocyanine green dye ala.associates/product-laun... #fluorescenceimaging #medicaldyes

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 24/09/2026

[ALA Client News] iPerf concludes promising clinical trial of novel dual-lumen femoral arterial cannula for cardiopulmonary support ala.associates/clinical/ipe... #clinicaltrial #ECMO #CEC

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 21/09/2026

[ALA Client News] Novadip secures €10.4 million financing to complete pivotal Phase 3 trial ala.associates/funding/nova... #funding #biotech

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 15/09/2026

[ALA Client News] Axoltis Pharma announces topline Phase 2 results for NX210c in Amyotrophic Lateral Sclerosis ala.associates/clinical/axo... #ALS #neurology #clinicaltrial

011

Andrew Lloyd ALA @andrewlloydala.bsky.social · 11/09/2026

🎙️ Media Training at Future4Care This week, our ALA team members Celine Gonzalez and Lorraine Walters shared practical advice with startups on interview preparation, key messages and building strong relationships with journalists, investors and KOLs. Thanks to everyone who joined! 🎥

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 08/09/2026

[ALA Client News] Ciliatech receives FDA IDE approval to initiate US feasibility study of INTERCIL® Uveal Spacer for glaucoma ala.associates/clinical/cil... #glaucoma #ophthalmology #medtech

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 08/09/2026

[ALA Client News] Clean Cells launches Next-Generation Sequencing (NGS) offering for viral safety testing ala.associates/product-laun... #biopharma #bioinformatics

001

Andrew Lloyd ALA @andrewlloydala.bsky.social · 02/09/2026

[ALA Client News] SOFIPACA et Région Sud Investissement renouvellent leur confiance à Provepharm pour accompagner une nouvelle étape de son développement ala.associates/funding/sofi... #PACA #pharma #chirurgie

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 01/09/2026

[ALA Client News] Amyl Therapeutics secures €8.25M Series A extension to validate novel neurodegenerative disease platform ala.associates/funding/amyl... #funding #biotech #neurology

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 30/07/2026

[ALA Client News] Clean Cells acquires Anaquant to expand analytical capabilities in biomanufacturing quality control ala.associates/corporate/cl... #biomanufacturing #qualitycontrol

010

Andrew Lloyd ALA @andrewlloydala.bsky.social · 17/07/2026

[Client Case Study] In 2026, ALA collaborated with @exciva-gmbh.bsky.social on three news releases covering a Series B fundraising, an executive appointment and a clinical trial launch The campaign generated 150+ media coverages, reaching an audience of 63M+ readers.

110

Andrew Lloyd ALA @andrewlloydala.bsky.social · 13/07/2026

[ALA Client News] Caixa Capital Risc rebrands as Criteria Capital Risc and targets €300M investment volume by 2030 ala.associates/corporate/ca... #funding #biotech #tech

020

Andrew Lloyd ALA @andrewlloydala.bsky.social · 02/07/2026

Celebrating our clients' media successes 🌟 We’re proud to share some of our clients’ highlights in the media published in June: 1️⃣ Grapheal in Aquatech. Vincent Bouchiat shared his expert insights on European regulations on PFAS and advancements in portable detection technologies.

100

Andrew Lloyd ALA @andrewlloydala.bsky.social · 29/06/2026

[ALA Client News] Genoskin Doubles US Foothold to Launch Local Primary Human Mast Cell Production for North American Customers ala.associates/corporate/ge... #mastcells #drugdiscovery

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 26/06/2026

🎙️[ALA Client in the News] Tune into the latest episode of Med Tech Gurus, where Philippe Bencteux, CEO of Robocath joins Thomas Hickey to discuss how robotic platforms are redefining precision, safety, and access in cardiovascular procedures. www.youtube.com/watch?v=L3KA... #cardiovascular #robotics

youtube.com

Robotics in the Cath Lab | Philippe Bencteux, MD | The Future of Robotic Angioplasty

YouTube video by Med Tech Gurus

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 24/06/2026

[ALA Client News] Kayentis launches interactive eConsent solution to simplify and improve patient understanding of clinical trials ala.associates/product-laun... #clinicaltrials #digitalhealth #eCOA

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 23/06/2026

[ALA Client News] Meteor Biotech joins consortium on seven-year brain organoids commercialization project ala.associates/partnership/... #neurology #drugdiscovery

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 22/06/2026

We attended @vivatech.bsky.social 2026 in Paris last week! An incredible opportunity to connect with some of the most innovative companies shaping the future of technology and healthcare. We look forward to sharing new inspiring stories and news in the coming weeks #VivaTech2026 #deeptech

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 18/06/2026

[ALA Client News] Clean Cells acquires Stem Genomics to strengthen cell therapy quality control and expand US presence ala.associates/corporate/cl... #biopharma #stemcells

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 17/06/2026

[ALA Client News] Vygon Corporation receives Health Canada approval to commercialize Stiletto™ extended dwell catheters ala.associates/product-laun... #medtech #hospital @vygongroup.bsky.social

022

Andrew Lloyd ALA @andrewlloydala.bsky.social · 17/06/2026

[ALA Client News] Meteor Biotech delivers talk at Spatial Omics 2026 on gaps in spatial biology mapping ala.associates/events/meteo... #SpatialOmics @vibtrainconf.bsky.social

010

Andrew Lloyd ALA @andrewlloydala.bsky.social · 12/06/2026

💡TIP #4: Tailor your language to the media you are speaking to It’s important to adapt how you explain your technology to different audiences. Specialized and trade media require a different approach. They may speak your technical language, but they might not be fluent. #PR #mediatraining

100

Andrew Lloyd ALA @andrewlloydala.bsky.social · 08/06/2026

[ALA Client News] Grapheal secures €2.5M from EIC Accelerator program to develop fast, field-deployable graphene sensors for ultra-trace, real-time PFAS detection ala.associates/funding/18767/ @ec.europa.eu #PFAS #EIC #deeptech

020

Andrew Lloyd ALA @andrewlloydala.bsky.social · 04/06/2026

Celebrating our clients' media successes 🌟 Here are some of our May highlights: 1️⃣ Estelle Haenel, CMO of Kayentis authored an article for International Clinical Trials on the value of wearables in eCOAs.

100

Andrew Lloyd ALA @andrewlloydala.bsky.social · 29/05/2026

💡TIP #3: if all spokespersons are media-trained, the delivery of your company messages will be consistent and stronger -> Interested in media training? See how ALA’s media training has helped our clients feel more confident and prepared for every interview

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 28/05/2026

[ALA Client News] Cathpax roll-outs new radiation protection system Nova-X® across EMEA following very promising clinical results ala.associates/clinical/cat... #medtech #neuroradiology

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 27/05/2026

[ALA Client News] BLEEDnFIRE Therapeutics launches with non-dilutive funding to advance first-in-class pan-indication therapy for rare bleeding disorders ala.associates/funding/blee... #hemophilia #innovation #hematology @inselgruppe.bsky.social @unibe.ch

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 21/05/2026

Celebrating our clients' media successes 🌟 Here are some of our April highlights: 1️⃣ Exciva in Drug Discovery World. The biotech company has dosed the first patient in a clinical trial evaluating the safety and efficacy of Deraphan for the treatment of agitation in patients with #Alzheimers disease.

100

Andrew Lloyd ALA @andrewlloydala.bsky.social · 12/05/2026

[ALA Client News] Exciva appoints distinguished biopharma leader Mark Altmeyer as chairman of the board ala.associates/appointment/... #alzheimers #neuropsychiatric #biopharma

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 11/05/2026

[ALA Client News] Robocath completes enrollment in First-In-Human (FIH) study of next-gen robotic platform in interventional cardiology ala.associates/clinical/rob... #robotics #cardiology #clinicaltrials

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 28/04/2026

[ALA Client News] Exciva doses first patient in Phase 2/3 trial of Deraphan for agitation in Alzheimer’s disease and extends Series B round ala.associates/clinical/exc... #alzheimers #clinicaltrial #seriesB

100

Andrew Lloyd ALA @andrewlloydala.bsky.social · 28/04/2026

[ALA Client News] Kahimmune Therapeutics signs agreement for scientific collaboration with @gustaveroussy.fr ala.associates/partnership/... #biotech #oncology

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 27/04/2026

🌟 Celebrating our clients’ media successes! March was a month of collaborations for ALA clients, here are our highlights: 1️⃣ Kayentis’ CMO Estelle Haenel spoke with BioXconomy about their new strategic partnership with Perceptive eClinical, tackling digital complexity in global clinical trials.

100

Andrew Lloyd ALA @andrewlloydala.bsky.social · 15/04/2026

[ALA Client News] Kayentis and RWS join forces to improve data confidence in neuroscience clinical trials ala.associates/partnership/... #neuroscience #clinicaltrials #digitalhealth #pharma

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 13/04/2026

[ALA Client News] Clean Cells and Naobios showcase complete end-to-end viral vaccines and vector solutions at BIO KOREA 2026 ala.associates/events/clean... #BIOKOREA2026

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 26/03/2026

Celebrating our clients' media successes 🌟 1️⃣ @vygongroup.bsky.social in @lesechosfr.bsky.social. Acquired Stiletto®, boosting vascular access leadership. 2️⃣ PLL Therapeutics in @neurologylive.bsky.social. Positive stage I results of phase I/II trial in ALS. #PR #biotech #medtech

121

Andrew Lloyd ALA @andrewlloydala.bsky.social · 24/03/2026

[ALA Client News] Perceptive eClinical and Kayentis partner to tackle increasing digital system complexity in global clinical trials ala.associates/partnership/... #clinicaltrials #digitalhealth #biotech #pharma

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 24/03/2026

[ALA Client News] iPerf enrolls first patient in clinical trial of innovative dual-flow femoral arterial cannula for cardiopulmonary support ala.associates/clinical/ipe... @ap-hp.bsky.social #cardiovascular #cannula #medtech

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 18/03/2026

[ALA Client News] Genoskin Showcases HypoSkin® Ex Vivo Platform at @sotoxicology.bsky.social Annual Meeting ala.associates/events/genos... #immunology #2026SOT

011

Andrew Lloyd ALA @andrewlloydala.bsky.social · 18/03/2026

[ALA Client News] Bio‑Sourcing and Tiny Cargo join forces to develop oral delivery therapies of monoclonal antibodies using goat‑milk exosomes ala.associates/partnership/... #exosomes #biologics

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 09/03/2026

[ALA Client News] Naobios and SGS partner to manufacture Respiratory Syncytial Virus (RSV) challenge agent ala.associates/partnership/... #RSV #vaccines

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 25/02/2026

[ALA Client News] SeaBeLife welcomes Professor Eric Souied to its scientific committee ala.associates/appointment/... #AMD #ophthalmology #biotech

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 23/02/2026

[Client Case Study] ALA has recently collaborated with ErVimmune, a biotech company developing next-generation cancer vaccines and cell therapies that target ‘cold tumors’ to announce a €17M Series A funding To date, the news release has reached an audience of 46.6M readers.

100

Andrew Lloyd ALA @andrewlloydala.bsky.social · 18/02/2026

[ALA Client News] PLL Therapeutics reports positive safety and tolerability results from phase I/II trial in #ALS (Amyotrophic Lateral Sclerosis) ala.associates/clinical/pll... #clinicaltrials #raredisease #phase1results

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 11/02/2026

We proudly support #InternationalWomenandGirlsinSTEMDay @unesco.org org has curated an immersive virtual exhibition taking visitors on a journey through history highlighting the achievements of women who have made groundbreaking contributions to in #STEM Learn more👇 www.unesco.org/en/virtual-s...

010

Andrew Lloyd ALA @andrewlloydala.bsky.social · 10/02/2026

[ALA Client News] @vygongroup.bsky.social acquires Stiletto® and its SlipStream™ technology from Avia Vascular ala.associates/corporate/vy... #medicaldevices #vascularaccess

010

Andrew Lloyd ALA @andrewlloydala.bsky.social · 02/02/2026

[ALA Client News] Kahimmune Therapeutics signs exclusive licensing agreement with @gustaveroussy.fr and SATT Paris-Saclay ala.associates/corporate/ka... #biotech #oncology

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 28/01/2026

[Client News] Kayentis and @actigraph.bsky.social join forces to deliver integrated eCOA solution measuring and improving wearable technology adherence in clinical trials 👉Want to learn more? ala.associates/partnership/... #wearable #clinicaltrials

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 28/01/2026

[Client News] En Carta Diagnostics receives @fda.gov Breakthrough Device Designation for EC Pocket Lyme test ala.associates/regulatory/e... #regulatory #diagnostics #LymeDisease

000

Andrew Lloyd ALA @andrewlloydala.bsky.social · 27/01/2026

[Client News] Robocath launches First-In-Human (FIH) clinical study of second-generation robot with unique capabilities in coronary artery disease ala.associates/clinical/rob... #medtech #trial

000